Analytical Data
-
Gene name
NOVA1
- Application
-
Alternative Names
Onconeural ventral antigen 1; Paraneoplastic Ri antigen; Ventral neuron-specific protein 1; RNA-binding protein Nova-1
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P51513
-
Expression Region
Ala292~Gly507
-
Molecular Weight
25kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
NOVA1 is a member of the Nova family of RNA-binding proteins that play crucial roles in the regulation of alternative splicing, a fundamental process in gene expression. Studying NOVA1 is significant as it is implicated in various neurodevelopmental disorders and the progression of certain cancers. Originally identified for its involvement in the central nervous system, NOVA1 contributes to the splicing of pre-mRNAs, influencing neuronal differentiation and synaptic function. Research has revealed that dysregulation of NOVA1 can lead to aberrant splicing events, which are linked to diseases such as autism spectrum disorders and specific types of brain tumors. Moreover, NOVA1's interaction with RNA influences cellular responses to stress, making it a potential target for therapeutic interventions. By exploring NOVA1 recombinant protein, researchers aim to better understand its structure, function, and the molecular mechanisms underlying its role in health and disease. Investigating NOVA1 may provide insights into novel treatment strategies for disorders where splicing misregulation is a key factor. Overall, NOVA1 is a pivotal focus in the realm of molecular biology, with ongoing research efforts aimed at elucidating its contribution to fundamental biological processes and disease pathology.
